Astrazeneca PLC (Spons. ADRs)
[WKN: 886715 | ISIN: US0463531089]
Aktienkurse
64,000€ 1,99%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid: Ask:
Reuters Kategorien
dpa-AFX Compact / dpa-AFX PRO Kategorien
Traderfox: dpa-AFX ProFeed Kategorien
dpa-AFX ProFeed Kategorien

AstraZeneca to acquire Fusion

19 March 2024 AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer Includes actinium-based clinical-stage radioconjugate targeting PSMA…

AstraZeneca: Rating gesenkt

Frankfurt (www.aktiencheck.de) - Rating-Update: Die Analysten von ODDO BHF stufen die Aktie von AstraZeneca plc (ISIN: GB0009895292, WKN: 886455, Ticker-Symbol: ZEG,…

AstraZeneca to acquire Amolyt

14 March, 2024 AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline Amolyt development portfolio includes Phase III asset with potential to address…

EMA validates Dato-DXd MAAs for NSQ NSCLC and BC

4 March 2024 Two datopotamab deruxtecan applications validated in the EU for patients with advanced nonsquamous non-small cell lung cancer or HR-positive, HER2-negative…

Total Voting Rights

1 March 2024 15:00 GMT Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct…

Aradhana Sarin

Aradhana Sarin led deals to expand AstraZenecas drug pipeline, and transformed the finance function to improve employee retention and productivity.…

Acquisition of Gracell completed

22 February 2024 Acquisition of Gracell completed AstraZeneca today announced the successful completion of the acquisition (https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-to-acquire-gracell-furthering-cell-therapy-ambition-across-oncology-and-autoimmune-diseases.html) of Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a…

Director/PDMR Shareholding

22 February 2024 11:00 GMT Transaction by Person Discharging Managerial Responsibilities AstraZeneca PLC (the Company) announced that, on 20 February 2024, an…

AstraZeneca prices a $5bn bond offering

22 February 2024 07:00 GMT AstraZeneca prices a $5bn bond offering AstraZeneca PLC ("AstraZeneca") announces that its wholly owned subsidiary AstraZeneca Finance LLC, priced…

Filing of Form 20-F with SEC

21 February 2024 07:00 GMT Filing of Annual Report on Form 20-F with the US Securities and Exchange Commission AstraZeneca PLC (the Company) announced…

AstraZeneca completes acquisition of Icosavax

19 February 2024 Acquisition of Icosavax Completed AstraZeneca announced today the successful completion of the acquisition of Icosavax, Inc., a US-based clinical-stage…

UBS stuft ASTRAZENECA auf Sell

ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Astrazeneca auf "Sell" mit einem Kursziel von 9900 Pence belassen. Die…